NEW YORK (GenomeWeb) – HTG Molecular Diagnostics said today that it has signed a research agreement with Spain's Instituto Valenciano de Oncología (IVO) to develop and validate a breast cancer recurrence risk score using the company's technology.

Under the terms of the deal, the partners will use HTG's EdgeSeq Oncology biomarker panel to develop a breast cancer recurrence risk score based on genes differentially expressed in patients with low and high risk of recurrence. Additional terms were not disclosed.